Rigel Pharmaceuticals Inc. (RIGL)

4.19
0.31 8.00
NASDAQ : Health Technology
Prev Close 3.88
Open 3.84
Day Low/High 3.75 / 4.11
52 Wk Low/High 2.14 / 4.71
Volume 2.07M
Avg Volume 1.93M
Exchange NASDAQ
Shares Outstanding 147.37M
Market Cap 549.69M
EPS -0.60
P/E Ratio 411.00
Div & Yield N.A. (N.A)

Latest News

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 50.6% Annualized Using Options

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 50.6% Annualized Using Options

Investors considering a purchase of Rigel Pharmaceuticals Inc shares, but tentative about paying the going market price of $3.89/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June put at the $2.50 strike, which has a bid at the time of this writing of 35 cents.

Rigel Announces Departure Of Chief Financial Officer

Rigel Announces Departure Of Chief Financial Officer

Launches Search for Chief Financial Officer with Commercial-Stage Expertise

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 20% Using Options

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 20% Using Options

Investors considering a purchase of Rigel Pharmaceuticals Inc shares, but tentative about paying the going market price of $3.87/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $2.50 strike, which has a bid at the time of this writing of 50 cents.

Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

Dimension Therapeutics said Oct. 3 it has agreed to sell to Ultragenyx Pharmaceutical for $6 a share in cash or about $151M.

Rigel Rises on Update on FDA Review of Bleeding Disorder Treatment

Rigel Rises on Update on FDA Review of Bleeding Disorder Treatment

The South San Francisco, Calif.-based firm said the U.S. Food and Drug Administration indicated that it does not plan to conduct an Oncology Drugs Advisory Committee meeting to discuss Rigel's new drug application for fostamatinib in chronic or persistent immune thrombocytopenia.

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy shares rose in premarket trading on Aug. 31 after plunging Wednesday on the heels of disappointing data in a Phase 3 study of Otividex in patients with Meniere's disease.

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 30.6% Annualized Using Options

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 30.6% Annualized Using Options

Investors considering a purchase of Rigel Pharmaceuticals Inc shares, but tentative about paying the going market price of $2.85/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2018 put at the $2.50 strike, which has a bid at the time of this writing of 55 cents.

Biotech Movers: Clovis, Seattle Genetics, Rigel

Biotech Movers: Clovis, Seattle Genetics, Rigel

Clovis Oncology, Seattle Genetics and Rigel Pharmaceuticals were among the biotech stock movers in premarket trading on June 19.

Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers

Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers

Arena Pharmaceuticals, Rigel Pharmaceuticals and Cytokinetics were among the biotech stock movers in premarket trading on Tuesday.

Immunomedics, Mylan Lead Biotech Movers

Immunomedics, Mylan Lead Biotech Movers

Investors weren't completely distracted by the Affordable Care Act debate.

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 18% Using Options

Investors eyeing a purchase of Rigel Pharmaceuticals Inc stock, but cautious about paying the going market price of $2.79/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $2.50 strike, which has a bid at the time of this writing of 45 cents.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Ironwood Pharmaceuticals, Rigel Pharmaceuticals and FibroGen were among the biotech stock movers in premarket trading on Monday.

First Week Of RIGL February 2017 Options Trading

First Week Of RIGL February 2017 Options Trading

Investors in Rigel Pharmaceuticals Inc saw new options begin trading this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the RIGL options chain for the new February 2017 contracts and identified the following put contract of particular interest.

TheStreet Quant Rating: D (Sell)